- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02026401
Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis
March 27, 2017 updated by: NGM Biopharmaceuticals, Inc
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Activity of NGM282 in Combination With Ursodeoxycholic Acid (UDCA) Administered for 28 Days in Patients With Primary Biliary Cirrhosis
The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Biliary Cirrhosis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia
- NGM Clinical Study Site 602
-
Sydney, New South Wales, Australia
- NGM Clinical Study Site 606
-
Sydney, New South Wales, Australia
- NGM Clinical Study Site 609
-
Sydney, New South Wales, Australia
- NGM Clinical Study Site 611
-
-
Queensland
-
Brisbane, Queensland, Australia
- NGM Clinical Study Site 614
-
-
South Australia
-
Adelaide, South Australia, Australia
- NGM Clinical Study Site 607
-
Adelaide, South Australia, Australia
- NGM Clinical Study Site 608
-
-
Victoria
-
Melbourne, Victoria, Australia
- NGM Clinical Study Site 601
-
Melbourne, Victoria, Australia
- NGM Clinical Study Site 604
-
Melbourne, Victoria, Australia
- NGM Clinical Study Site 613
-
-
-
-
Arizona
-
Phoenix, Arizona, United States
- NGM Clinical Study Site 103
-
-
California
-
Coronado, California, United States
- NGM Clinical Study Site 108
-
-
Michigan
-
Detroit, Michigan, United States
- NGM Clinical Study Site 101
-
-
North Carolina
-
Durham, North Carolina, United States
- NGM Clinical Study Site 105
-
-
Texas
-
Dallas, Texas, United States
- NGM Clinical Study Site 102
-
San Antonio, Texas, United States
- NGM Clinical Study Site 113
-
-
Virginia
-
Richmond, Virginia, United States
- NGM Clinical Study Site 104
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males or females, between 18 and 75 years of age, inclusive
- PBC diagnosis consistent with AASLD and EASL guidelines
- Stable dose of UDCA
Exclusion Criteria:
- Chronic liver disease of a non-PBC etiology
- Evidence of clinically significant hepatic decompensation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
|
EXPERIMENTAL: NGM282 Dose 1
|
|
EXPERIMENTAL: NGM282 Dose 2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Absolute change in plasma ALP from Baseline to Day 28
Time Frame: 28 days
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Absolute change in bilirubin from Baseline to Day 28
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2014
Primary Completion (ACTUAL)
December 1, 2014
Study Completion (ACTUAL)
December 1, 2014
Study Registration Dates
First Submitted
December 30, 2013
First Submitted That Met QC Criteria
January 2, 2014
First Posted (ESTIMATE)
January 3, 2014
Study Record Updates
Last Update Posted (ACTUAL)
March 28, 2017
Last Update Submitted That Met QC Criteria
March 27, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-0103
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Biliary Cirrhosis
-
University Health Network, TorontoUnknown
-
CymaBay Therapeutics, Inc.TerminatedPrimary Biliary Cirrhosis (PBC)Germany, United States, Canada, United Kingdom, Poland
-
Xijing Hospital of Digestive DiseasesUnknownPrimary Biliary CirrhosisChina
-
University of AarhusAarhus University Hospital; Hvidovre University HospitalRecruiting
-
CymaBay Therapeutics, Inc.RecruitingPrimary Biliary CirrhosisUnited States, Korea, Republic of, Belgium, Spain, France, Switzerland, Romania, United Kingdom, Austria, Israel, Australia, Argentina, Canada, Chile, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Czechia, New Zealand, Turke... and more
-
Target PharmaSolutions, Inc.Active, not recruitingBiliary Cirrhosis, PrimaryUnited States
-
IpsenActive, not recruitingPrimary Biliary CirrhosisUnited States, France, Spain, Belgium, Germany, Switzerland, Brazil, United Kingdom, Argentina, Canada, Chile, Italy, South Africa, Turkey
-
Instituto Mexicano del Seguro SocialActive, not recruitingPrimary Biliary CirrhosisMexico
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingPrimary Biliary CirrhosisChina
-
Zydus Therapeutics Inc.CompletedPrimary Biliary CirrhosisUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States